B-lymphocyte homeostasis and BLyS-directed immunotherapy in transplantation.

[1]  O. Martinez,et al.  MicroRNAs as Immune Regulators: Implications for Transplantation , 2010, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[2]  A. Hamilton,et al.  Targeted therapy in haematological malignancies , 2010, The Journal of pathology.

[3]  Michel C. Nussenzweig,et al.  Germinal center reutilization by newly activated B cells , 2009, The Journal of experimental medicine.

[4]  M. Sarwal,et al.  BAFF may modulate the rate of B-cell repopulation after rituximab therapy for acute renal transplant rejection. , 2009, Transplantation.

[5]  R. Redfield,et al.  B-cell tolerance in transplantation: is repertoire remodeling the answer? , 2009, Expert review of clinical immunology.

[6]  S. Knechtle,et al.  Overcoming Chronic Rejection-Can it B? , 2009, Transplantation.

[7]  M. Cancro.  Signalling crosstalk in B cells: managing worth and need , 2009, Nature Reviews Immunology.

[8]  R. Colvin,et al.  B‐Cell Immunity in the Context of T‐Cell Tolerance after Combined Kidney and Bone Marrow Transplantation in Humans , 2009, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[9]  Anne-Kathrin Kienzler,et al.  B-cell activating factor receptor deficiency is associated with an adult-onset antibody deficiency syndrome in humans , 2009, Proceedings of the National Academy of Sciences.

[10]  J. Fechner,et al.  BAFF Is Increased in Renal Transplant Patients Following Treatment with Alemtuzumab , 2009, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[11]  I. Doxiadis,et al.  Transplantation of highly sensitized patients via the acceptable mismatch program or desensitization? We need both , 2009, Current opinion in organ transplantation.

[12]  Luigi Naldini,et al.  Exploiting and antagonizing microRNA regulation for therapeutic and experimental applications , 2009, Nature Reviews Genetics.

[13]  Kenneth G. C. Smith,et al.  B-cell-depleting induction therapy and acute cellular rejection. , 2009, The New England journal of medicine.

[14]  P. Emery,et al.  Atacicept, a novel B cell-targeting biological therapy for the treatment of rheumatoid arthritis , 2009, Expert opinion on biological therapy.

[15]  X. He,et al.  Abnormal high expression of B-cell activating factor belonging to the TNF superfamily (BAFF) associated with long-term outcome in kidney transplant recipients. , 2009, Transplantation proceedings.

[16]  P. Terasaki,et al.  Abrogation of Anti-HLA Antibodies via Proteasome Inhibition , 2009, Transplantation.

[17]  A. Saraux,et al.  Critical analysis of rituximab-induced serological changes in connective tissue diseases. , 2009, Autoimmunity reviews.

[18]  Darshana Dadhania,et al.  MicroRNA expression profiles predictive of human renal allograft status , 2009, Proceedings of the National Academy of Sciences.

[19]  S. Grey,et al.  CD4+CD25+ T-Cells Control Autoimmunity in the Absence of B-Cells , 2009, Diabetes.

[20]  A. Rahmel,et al.  Successful Deceased-Donor Kidney Transplantation in Crossmatch-Positive Patients With Peritransplant Plasma Exchange and Rituximab , 2009, Transplantation.

[21]  L. Otten,et al.  CD93 is required for maintenance of antibody secretion and persistence of plasma cells in the bone marrow niche , 2009, Proceedings of the National Academy of Sciences.

[22]  S. Jacobs,et al.  Positive Cross‐Match Living Donor Kidney Transplantation: Longer‐Term Outcomes , 2009, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[23]  J. Xu,et al.  Memory Alloreactive B Cells and Alloantibodies Prevent Anti-CD154-Mediated Allograft Acceptance1 , 2009, The Journal of Immunology.

[24]  Klaus Rajewsky,et al.  MicroRNA Control in the Immune System: Basic Principles , 2009, Cell.

[25]  R. Ponce.  Preclinical Support for Combination Therapy in the Treatment of Autoimmunity with Atacicept , 2009, Toxicologic pathology.

[26]  So young Lee,et al.  Successful Renal Transplantation with Desensitization in Highly Sensitized Patients: A Single Center Experience , 2009, Journal of Korean medical science.

[27]  R. Alloway,et al.  Bortezomib Provides Effective Therapy for Antibody- and Cell-Mediated Acute Rejection , 2008, Transplantation.

[28]  M. Sarwal,et al.  A Randomized, Prospective Trial of Rituximab for Acute Rejection in Pediatric Renal Transplantation , 2008, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[29]  Hedda Wardemann,et al.  B-cell tolerance checkpoints in health and autoimmunity. , 2008, Current opinion in immunology.

[30]  M. Cancro,et al.  In Vivo BLyS/BAFF Neutralization Ameliorates Islet-Directed Autoimmunity in Nonobese Diabetic Mice1 , 2008, The Journal of Immunology.

[31]  Haiyan Xu,et al.  The Abnormal High Expression of B Cell Activating Factor Belonging to TNF Superfamily (BAFF) and Its Potential Role in Kidney Transplant Recipients , 2008, Cellular and Molecular Immunology.

[32]  B. Tanriover,et al.  High-dose intravenous immunoglobulin and rituximab treatment for antibody-mediated rejection after kidney transplantation: a cost analysis. , 2008, Transplantation proceedings.

[33]  J. Monroe,et al.  Tonic B cell antigen receptor signals supply an NF-κB substrate for prosurvival BLyS signaling , 2008, Nature Immunology.

[34]  B. Gatto.  Atacicept, a homodimeric fusion protein for the potential treatment of diseases triggered by plasma cells. , 2008, Current opinion in investigational drugs.

[35]  M. Stegall,et al.  Proteasome Inhibition Causes Apoptosis of Normal Human Plasma Cells Preventing Alloantibody Production , 2008, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[36]  Yun Hee Cho,et al.  BLyS inhibition eliminates primary B cells but leaves natural and acquired humoral immunity intact , 2008, Proceedings of the National Academy of Sciences.

[37]  S. Jordan,et al.  Acceptable Donor-Specific Antibody Levels Allowing for Successful Deceased and Living Donor Kidney Transplantation After Desensitization Therapy , 2008, Transplantation.

[38]  J. Merrill,et al.  Biologic activity and safety of belimumab, a neutralizing anti-B-lymphocyte stimulator (BLyS) monoclonal antibody: a phase I trial in patients with systemic lupus erythematosus , 2008, Arthritis research & therapy.

[39]  A. S. Muñoz,et al.  Rituximab in highly sensitized kidney transplant recipients. , 2008, Transplantation proceedings.

[40]  M. Madaio,et al.  Prevention of murine antiphospholipid syndrome by BAFF blockade. , 2008, Arthritis and rheumatism.

[41]  M. Sarwal,et al.  Characterization of intra-graft B cells during renal allograft rejection. , 2008, Kidney international.

[42]  A. Amante,et al.  Management of highly sensitized patients: capitol medical center experience. , 2008, Transplantation proceedings.

[43]  Junchao Cai,et al.  Human Leukocyte Antigen Antibodies and Chronic Rejection: From Association to Causation , 2008, Transplantation.

[44]  Michael P. Cancro,et al.  Homeostatic control of B lymphocyte subsets , 2008, Immunologic research.

[45]  S. Jordan,et al.  Rituximab and intravenous immune globulin for desensitization during renal transplantation. , 2008, The New England journal of medicine.

[46]  R. Colvin,et al.  INHIBITORY EFFECTS OF ATACICEPT (TACI-IG) ON CIRCULATING ANTIBODIES, B CELLS AND PLASMA CELLS IN ALLOSENSITIZED CYNOMOLGUS MONKEYS: 463 , 2008 .

[47]  U. Berg,et al.  ABO-Incompatible Kidney Transplantation Using Antigen-Specific Immunoadsorption and Rituximab: A 3-Year Follow-up , 2008, Transplantation.

[48]  M. Sarwal,et al.  "To B or not to B?" B-cells and graft rejection. , 2008, Transplantation.

[49]  Kenneth G. C. Smith,et al.  The B-cell response to protein antigens in immunity and transplantation. , 2008, Transplantation.

[50]  M. Cancro,et al.  Manipulating B cell homeostasis: a key component in the advancement of targeted strategies , 2008, Archivum Immunologiae et Therapiae Experimentalis.

[51]  R. Geha,et al.  Cutting Edge: The Dependence of Plasma Cells and Independence of Memory B Cells on BAFF and APRIL1 , 2008, The Journal of Immunology.

[52]  Meit A. Bjorndahl,et al.  Articles on similar topics can be found in the following Blood collections , 2006 .

[53]  V. Sharma,et al.  HLA-mismatched renal transplantation without maintenance immunosuppression. , 2008, The New England journal of medicine.

[54]  S. Korsmeyer,et al.  Multiple signaling pathways promote B lymphocyte stimulator dependent B-cell growth and survival. , 2008, Blood.

[55]  L. Wen,et al.  Treatment with CD20-specific antibody prevents and reverses autoimmune diabetes in mice. , 2007, The Journal of clinical investigation.

[56]  K. Kalunian,et al.  Reduced B lymphocyte and immunoglobulin levels after atacicept treatment in patients with systemic lupus erythematosus: results of a multicenter, phase Ib, double-blind, placebo-controlled, dose-escalating trial. , 2007, Arthritis and rheumatism.

[57]  M. Rickels,et al.  B lymphocyte–directed immunotherapy promotes long-term islet allograft survival in nonhuman primates , 2007, Nature Medicine.

[58]  R. Bram,et al.  TACI Is Required for Efficient Plasma Cell Differentiation in Response to T-Independent Type 2 Antigens1 , 2007, The Journal of Immunology.

[59]  J. Kearney,et al.  Lupus Susceptibility Genes May Breach Tolerance to DNA by Impairing Receptor Editing of Nuclear Antigen-Reactive B Cells1 , 2007, The Journal of Immunology.

[60]  A. Kirk,et al.  American Society of Transplantation Symposium on B Cells in Transplantation: Harnessing Humoral Immunity from Rodent Models to Clinical Practice , 2007, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[61]  L. Rostaing,et al.  Rituximab therapy for acute humoral rejection after kidney transplantation. , 2007, Transplantation.

[62]  J. Pers,et al.  BAFF-modulated repopulation of B lymphocytes in the blood and salivary glands of rituximab-treated patients with Sjögren's syndrome. , 2007, Arthritis and rheumatism.

[63]  N. Rajewsky,et al.  Regulation of the Germinal Center Response by MicroRNA-155 , 2007, Science.

[64]  C. Mayr,et al.  miR-150, a microRNA expressed in mature B and T cells, blocks early B cell development when expressed prematurely , 2007, Proceedings of the National Academy of Sciences.

[65]  I. Noronha,et al.  Detection of B lymphocytes (CD20+) in renal allograft biopsy specimens. , 2007, Transplantation proceedings.

[66]  P. Terasaki,et al.  Four‐year Follow‐up of a Prospective Trial of HLA and MICA Antibodies on Kidney Graft Survival , 2007, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[67]  P. Ravichandran,et al.  Combination treatment of low dose Anti-Thymocyte Globulin (ATG), Rituximab and high dose Sirolimus as induction agents in immune-conditioned recipients. , 2006, International immunopharmacology.

[68]  M. Zeier,et al.  Desensitization strategies enabling successful renal transplantation in highly sensitized patients , 2006, Clinical transplantation.

[69]  A. Naji,et al.  B Cell-Mediated Antigen Presentation Is Required for the Pathogenesis of Acute Cardiac Allograft Rejection1 , 2006, The Journal of Immunology.

[70]  X. Mariette,et al.  Increase of B cell-activating factor of the TNF family (BAFF) after rituximab treatment: insights into a new regulating system of BAFF production , 2006, Annals of the rheumatic diseases.

[71]  R. Brink.  Regulation of B cell self-tolerance by BAFF. , 2006, Seminars in immunology.

[72]  G. Widhopf,et al.  Alternative and classical NF-kappa B signaling retain autoreactive B cells in the splenic marginal zone and result in lupus-like disease. , 2006, Immunity.

[73]  Y. Becker,et al.  The emerging role of rituximab in organ transplantation , 2006, Transplant international : official journal of the European Society for Organ Transplantation.

[74]  W. Wallace,et al.  CD20+ Lymphocytes in Renal Allografts Are Associated with Poor Graft Survival in Pediatric Patients , 2006, Transplantation.

[75]  M. Cancro,et al.  Cutting Edge: Impaired Transitional B Cell Production and Selection in the Nonobese Diabetic Mouse1 , 2006, The Journal of Immunology.

[76]  M. Cancro,et al.  Space, Selection, and Surveillance: Setting Boundaries with BLyS1 , 2006, The Journal of Immunology.

[77]  M. Pescovitz,et al.  Presensitization: the problem and its management. , 2006, Clinical journal of the American Society of Nephrology : CJASN.

[78]  T. Dörner.  Crossroads of B cell activation in autoimmunity: rationale of targeting B cells. , 2006, The Journal of rheumatology. Supplement.

[79]  D. Hilbert,et al.  Circulating levels of B lymphocyte stimulator in patients with rheumatoid arthritis following rituximab treatment: relationships with B cell depletion, circulating antibodies, and clinical relapse. , 2006, Arthritis and rheumatism.

[80]  S. Dillon,et al.  An APRIL to remember: novel TNF ligands as therapeutic targets , 2006, Nature Reviews Drug Discovery.

[81]  L. West.  B-cell tolerance following ABO-incompatible infant heart transplantation. , 2006, Transplantation.

[82]  M. Pescovitz.  B cells: a rational target in alloantibody‐mediated solid organ transplantation rejection , 2006, Clinical transplantation.

[83]  N. Rajewsky,et al.  Silencing of microRNAs in vivo with ‘antagomirs’ , 2005, Nature.

[84]  J. Ravetch,et al.  Activating and inhibitory IgG Fc receptors on human DCs mediate opposing functions. , 2005, The Journal of clinical investigation.

[85]  J. Markmann,et al.  Development of anti-human leukocyte antigen class 1 antibodies following allogeneic islet cell transplantation. , 2005, Transplantation proceedings.

[86]  I. Doxiadis,et al.  Extending options for highly sensitized patients to receive a suitable kidney graft. , 2005, Current opinion in immunology.

[87]  R. Colvin,et al.  Antibody-mediated organ-allograft rejection , 2005, Nature Reviews Immunology.

[88]  W. Cook,et al.  Association of CD20+ Infiltrates with Poorer Clinical Outcomes in Acute Cellular Rejection of Renal Allografts , 2005, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[89]  V. Pantesco,et al.  The level of TACI gene expression in myeloma cells is associated with a signature of microenvironment dependence versus a plasmablastic signature. , 2005, Blood.

[90]  Shuang-quan Zhang,et al.  Immunological effects of refolded human soluble BAFF synthesized in Escherichia coli on murine B lymphocytes in vitro and in vivo. , 2005, The Japanese journal of physiology.

[91]  L. Miosge,et al.  Genes, pathways and checkpoints in lymphocyte development and homeostasis , 2005, Immunology and cell biology.

[92]  C. Goodnow,et al.  Cellular and genetic mechanisms of self tolerance and autoimmunity , 2005, Nature.

[93]  S. Kalled.  The role of BAFF in immune function and implications for autoimmunity , 2005, Immunological reviews.

[94]  K. Calame,et al.  Regulation of plasma-cell development , 2005, Nature Reviews Immunology.

[95]  K. Wood.  Is B Cell Tolerance Essential for Transplantation Tolerance? , 2005, Transplantation.

[96]  Yen-Ming Hsu,et al.  Selectivity of BAFF/BLyS and APRIL for binding to the TNF family receptors BAFFR/BR3 and BCMA. , 2005, Biochemistry.

[97]  L. Diehl,et al.  Importance of Cellular Microenvironment and Circulatory Dynamics in B Cell Immunotherapy1 , 2005, The Journal of Immunology.

[98]  D. Nemazee,et al.  The scope of receptor editing and its association with autoimmunity. , 2004, Current opinion in immunology.

[99]  T. Manser,et al.  B Cells Expressing Bcl-2 and a Signaling-Impaired BAFF-Specific Receptor Fail to Mature and Are Deficient in the Formation of Lymphoid Follicles and Germinal Centers1 , 2004, The Journal of Immunology.

[100]  J. Platt,et al.  Donor-specific B-cell tolerance after ABO-incompatible infant heart transplantation , 2004, Nature Medicine.

[101]  T. Phan,et al.  Excess BAFF rescues self-reactive B cells from peripheral deletion and allows them to enter forbidden follicular and marginal zone niches. , 2004, Immunity.

[102]  J. Cyster,et al.  Reduced competitiveness of autoantigen-engaged B cells due to increased dependence on BAFF. , 2004, Immunity.

[103]  D. Herzyk,et al.  Primary antibody response to keyhole limpet hemocyanin in rat as a model for immunotoxicity evaluation. , 2004, Toxicology.

[104]  N. Fineberg,et al.  Rituximab for reduction of anti-HLA antibodies in patients awaiting renal transplantation: 1. Safety, pharmacodynamics, and pharmacokinetics1 , 2004, Transplantation.

[105]  M. Pescovitz.  The use of rituximab, anti‐CD20 monoclonal antibody, in pediatric transplantation , 2004, Pediatric transplantation.

[106]  R. Bram,et al.  BCMA Is Essential for the Survival of Long-lived Bone Marrow Plasma Cells , 2004, The Journal of experimental medicine.

[107]  P. Halloran,et al.  The role of B cells and alloantibody in the host response to human organ allografts , 2003, Immunological reviews.

[108]  M. Nussenzweig,et al.  Predominant Autoantibody Production by Early Human B Cell Precursors , 2003, Science.

[109]  S. Aiba,et al.  Accelerated antigen presentation and elicitation of humoral response in vivo by FcγRIIB- and FcγRI/III-mediated immune complex uptake☆ , 2003 .

[110]  J. Monroe,et al.  Incomplete Activation of CD4 T Cells by Antigen-Presenting Transitional Immature B Cells: Implications for Peripheral B and T Cell Responsiveness1 , 2003, The Journal of Immunology.

[111]  T. Larson,et al.  Overcoming a Positive Crossmatch in Living‐Donor Kidney Transplantation , 2003, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[112]  I. Maclennan,et al.  NF-κB1 p50 Is Required for BLyS Attenuation of Apoptosis but Dispensable for Processing of NF-κB2 p100 to p52 in Quiescent Mature B Cells1 , 2003, The Journal of Immunology.

[113]  M. Sarwal,et al.  Molecular heterogeneity in acute renal allograft rejection identified by DNA microarray profiling. , 2003, The New England journal of medicine.

[114]  M. Cancro,et al.  Cutting Edge: B Cell Receptor Signals Regulate BLyS Receptor Levels in Mature B Cells and Their Immediate Progenitors 1 , 2003, The Journal of Immunology.

[115]  J. Monroe,et al.  Transitional B cells: step by step towards immune competence. , 2003, Trends in immunology.

[116]  Antonio Lanzavecchia,et al.  Maintenance of Serological Memory by Polyclonal Activation of Human Memory B Cells , 2002, Science.

[117]  D. Hilbert,et al.  Cutting Edge: BLyS Enables Survival of Transitional and Mature B Cells Through Distinct Mediators1 , 2002, The Journal of Immunology.

[118]  E. L. Luning Prak,et al.  Analysis of B cell receptor production and rearrangement. Part I. Light chain rearrangement. , 2002, Seminars in immunology.

[119]  J. Katz,et al.  The North American Immune Tolerance Registry: Practices, Outcomes, Outcome Predictors , 2002, Thrombosis and Haemostasis.

[120]  V. Dixit,et al.  Identification of a novel receptor for B lymphocyte stimulator that is mutated in a mouse strain with severe B cell deficiency , 2001, Current Biology.

[121]  S. Dillon,et al.  TACI-Ig neutralizes molecules critical for B cell development and autoimmune disease. impaired B cell maturation in mice lacking BLyS. , 2001, Immunity.

[122]  W. Baldwin,et al.  PASSIVE TRANSFER OF ALLOANTIBODIES RESTORES ACUTE CARDIAC REJECTION IN IgKO MICE1,2 , 2001, Transplantation.

[123]  A. Caton,et al.  Virus-Induced Maturation and Activation of Autoreactive Memory B Cells , 2000, The Journal of experimental medicine.

[124]  J. Tschopp,et al.  Baff Mediates Survival of Peripheral Immature B Lymphocytes , 2000, The Journal of experimental medicine.

[125]  M. Moser,et al.  B Lymphocytes Regulate Dendritic Cell (Dc) Function in Vivo , 2000, The Journal of experimental medicine.

[126]  V. Kouskoff,et al.  B cell receptor expression level determines the fate of developing B lymphocytes: receptor editing versus selection. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[127]  Don Foster,et al.  TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease , 2000, Nature.

[128]  J. Tschopp,et al.  Mice Transgenic for Baff Develop Lymphocytic Disorders along with Autoimmune Manifestations , 1999, The Journal of experimental medicine.

[129]  Amy S Orr,et al.  BLyS: member of the tumor necrosis factor family and B lymphocyte stimulator. , 1999, Science.

[130]  J. Tschopp,et al.  BAFF, a Novel Ligand of the Tumor Necrosis Factor Family, Stimulates B Cell Growth , 1999, The Journal of experimental medicine.

[131]  E. Puré,et al.  Characterization of anergic anti-DNA B cells: B cell anergy is a T cell-independent and potentially reversible process. , 1999, International immunology.

[132]  K. Bürki,et al.  Contribution of donor-specific antibodies to acute allograft rejection: evidence from B cell-deficient mice. , 1998, Transplantation.

[133]  L. Mandik-Nayak,et al.  Regulation of Anti–double-stranded DNA B Cells in Nonautoimmune Mice: Localization to the T–B Interface of the Splenic Follicle , 1997, The Journal of experimental medicine.

[134]  G. Kelsoe,et al.  Distinctive characteristics of germinal center B cells. , 1997, Seminars in immunology.

[135]  A. Naji,et al.  B-Cells Are Required for the Initiation of Insulitis and Sialitis in Nonobese Diabetic Mice , 1997, Diabetes.

[136]  K. Toellner,et al.  The changing preference of T and B cells for partners as T‐dependent antibody responses develop , 1997, Immunological reviews.

[137]  M. Cancro,et al.  Bcmd governs recruitment of new B cells into the stable peripheral B cell pool in the A/WySnJ mouse. , 1996, Journal of immunology.

[138]  P. Matzinger,et al.  Long-lasting CD8 T cell memory in the absence of CD4 T cells or B cells , 1996, The Journal of experimental medicine.

[139]  K. Shokat,et al.  Antigen-induced B-cell death and elimination during germinal-centre immune responses , 1995, Nature.

[140]  J. Monroe,et al.  Engagement of the antigen-receptor on immature murine B lymphocytes results in death by apoptosis. , 1995, Journal of immunology.

[141]  J. Cyster,et al.  Competition for follicular niches excludes self-reactive cells from the recirculating B-cell repertoire , 1994, Nature.

[142]  R. Hardy,et al.  Deletion and editing of B cells that express antibodies to DNA. , 1994, Journal of immunology.

[143]  A. Basten,et al.  Reduced life span of anergic self-reactive B cells in a double- transgenic model , 1994, The Journal of experimental medicine.

[144]  M. Cancro,et al.  Peripheral B cell maturation. II. Heat-stable antigen(hi) splenic B cells are an immature developmental intermediate in the production of long-lived marrow-derived B cells. , 1993, Journal of immunology.

[145]  K. Fuller,et al.  T cells within germinal centers are specific for the immunizing antigen. , 1993, Journal of immunology.

[146]  Jing Wu,et al.  B-cell apoptosis induced by antigen receptor crosslinking is blocked by a T-cell signal through CD40 , 1993, Nature.

[147]  S. Camper,et al.  Receptor editing: an approach by autoreactive B cells to escape tolerance , 1993, The Journal of experimental medicine.

[148]  M. Cancro,et al.  Peripheral B cell maturation. I. Immature peripheral B cells in adults are heat-stable antigenhi and exhibit unique signaling characteristics. , 1992, Journal of immunology.

[149]  T. Honjo,et al.  Antigen-induced apoptotic death of Ly-1 B cells responsible for autoimmune disease in transgenic mice , 1992, Nature.

[150]  C. Hayes,et al.  A single autosomal gene defect severely limits IgG but not IgM responses in B lymphocyte‐deficient A/WySnJ mice , 1992, European journal of immunology.

[151]  G. Morahan,et al.  Peripheral deletion of self-reactive B cells , 1991, Nature.

[152]  C. Goodnow,et al.  Elimination from peripheral lymphoid tissues of self-reactive B lymphocytes recognizing membrane-bound antigens , 1991, Nature.

[153]  C. Hayes,et al.  Phenotypic and genetic characterization of a unique B lymphocyte deficiency in strain A/WySnJ mice , 1991, European journal of immunology.

[154]  R. Hardy,et al.  Expression of anti-DNA immunoglobulin transgenes in non-autoimmune mice , 1991, Nature.

[155]  D. Nemazee,et al.  Clonal deletion of B lymphocytes in a transgenic mouse bearing anti-MHC class I antibody genes , 1989, Nature.

[156]  E. Berntorp,et al.  Induction of immune tolerance in patients with hemophilia and antibodies to factor VIII by combined treatment with intravenous IgG, cyclophosphamide, and factor VIII. , 1988, The New England journal of medicine.

[157]  A. Boss.  To B or not to B ? , 1987, Nature.

[158]  G. Nossal,et al.  Evidence for the clonal abortion theory of B-lymphocyte tolerance , 1975, The Journal of experimental medicine.

[159]  J. Sprent,et al.  Circulating T and B lymphocytes of the mouse. II. Lifespan. , 1973, Cellular immunology.

[160]  J. Sprent,et al.  Circulating T and B lymphocytes of the mouse. I. Migratory properties. , 1973, Cellular immunology.

[161]  D. G. Osmond,et al.  Migration of bone marrow lymphocytes demonstrated by selective bone marrow labeling with thymidine‐H3 , 1970, The Anatomical record.

[162]  B. Diamond,et al.  Effect of long-term belimumab treatment on B cells in systemic lupus erythematosus: extension of a phase II, double-blind, placebo-controlled, dose-ranging study. , 2010, Arthritis and rheumatism.

[163]  I. Grewal,et al.  Targeting of BAFF and APRIL for autoimmunity and oncology. , 2009, Advances in experimental medicine and biology.

[164]  C. Kempton,et al.  How we treat a hemophilia A patient with a factor VIII inhibitor. , 2009, Blood.

[165]  R. Colvin.  Pathology of chronic humoral rejection. , 2009, Contributions to nephrology.

[166]  H. Shirakawa,et al.  Evaluation of two different preconditioning regimens for ABO-incompatible living kidney donor transplantation. A comparison of splenectomy vs. rituximab-treated non-splenectomy preconditioning regimens. , 2009, Contributions to nephrology.

[167]  Z. Kovačević,et al.  Our first experiences in applying an original method for removal of ABO-isoagglutinins in ABO-incompatible kidney recipients. , 2009, Vojnosanitetski pregled.

[168]  Trial watch: BLYS-targeted antibody shows promise in Phase III SLE trial , 2009, Nature Reviews Drug Discovery.

[169]  M. Cancro,et al.  The BLyS Family: Toward a Molecular Understanding of B Cell Homeostasis , 2008, Cell Biochemistry and Biophysics.

[170]  A. Munafo,et al.  Atacicept in patients with rheumatoid arthritis: results of a multicenter, phase Ib, double-blind, placebo-controlled, dose-escalating, single- and repeated-dose study. , 2008, Arthritis and rheumatism.

[171]  C. Ding.  Belimumab, an anti-BLyS human monoclonal antibody for potential treatment of inflammatory autoimmune diseases. , 2008, Expert opinion on biological therapy.

[172]  M. Nussenzweig,et al.  B-cell self-tolerance in humans. , 2007, Advances in immunology.

[173]  L. Klareskog,et al.  Treatment with rituximab affects both the cellular and the humoral arm of the immune system in patients with SLE. , 2007, Clinical immunology.

[174]  M. Suchyta.  To B or not to B?: it still is the question. , 2004, Chest.

[175]  I. Maclennan,et al.  NF-kappa B1 p50 is required for BLyS attenuation of apoptosis but dispensable for processing of NF-kappa B2 p100 to p52 in quiescent mature B cells. , 2003, Journal of immunology.

[176]  N. A. MITCttlSON.  STUDIES ON THE IMMUNOLOGICAL RESPONSE TO FOREIGN TUMOR TRANSPLANTS IN THE MOUSE , 2003 .

[177]  S. Aiba,et al.  Accelerated antigen presentation and elicitation of humoral response in vivo by FcgammaRIIB- and FcgammaRI/III-mediated immune complex uptake. , 2003, Cellular immunology.

[178]  Melinda Fitzgerald,et al.  Immunol. Cell Biol. , 1995 .